Paper23239809
Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells.
Minami D and 9 others. Mol Cancer Res, 2013. Cited by 53 papers, by iCite.
Cite this record
ConductScience Library. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Papers, record 23239809. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23239809
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Cisplatin | Major topic |
| Lung Neoplasms | Major topic |
| PTEN Phosphohydrolase | Major topic |
| Phthalazines | Major topic |
| Piperazines | Major topic |
| Animals | |
| Cell Line, Tumor | |
| DNA Damage | |
| DNA Repair | |
| Drug Synergism | |
| Female | |
| Humans | |
| Mice | |
| Mice, Nude | |
| Poly(ADP-ribose) Polymerase Inhibitors | |
| Poly(ADP-ribose) Polymerases | |
| Transfection | |
| Xenograft Model Antitumor Assays |
Source PubMed
Cited by33
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 53 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39201255 | An Overview of Altered Pathways Associated with Sensitivity to Platinum-Based Chemotherapy in Neuroendocrine Tumors: Strengths and Prospects. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39201255 | PubMed |
| 39085400 | Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. | NPJ Precis Oncol | 2024 | https://conductscience.org/library/papers/39085400 | PubMed |
| 38873997 | Polydatin, a potential NOX5 agonist, synergistically enhances antitumor activity of cisplatin by stimulating oxidative stress in non‑small cell lung cancer. | Int J Oncol | 2024 | https://conductscience.org/library/papers/38873997 | PubMed |
| 38496700 | Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review. | Transl Lung Cancer Res | 2024 | https://conductscience.org/library/papers/38496700 | PubMed |
| 38323288 | Novel dual action PARP and microtubule polymerization inhibitor AMXI-5001 powerfully inhibits growth of esophageal carcinoma both alone and in combination with radiotherapy. | Am J Cancer Res | 2024 | https://conductscience.org/library/papers/38323288 | PubMed |
| 37077938 | RAB27B Drives a Cancer Stem Cell Phenotype in NSCLC Cells Through Enhanced Extracellular Vesicle Secretion. | Cancer Res Commun | 2023 | https://conductscience.org/library/papers/37077938 | PubMed |
| 35018214 | Transcriptomics reveals in vivo efficacy of PARP inhibitor combinatorial synergy with platinum-based chemotherapy in human non-small cell lung carcinoma models. | Oncotarget | 2022 | https://conductscience.org/library/papers/35018214 | PubMed |
| 34335884 | Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells. | Exp Ther Med | 2021 | https://conductscience.org/library/papers/34335884 | PubMed |
| 32860347 | Dihydrotanshinone I inhibits ovarian cancer cell proliferation and migration by transcriptional repression of PIK3CA gene. | J Cell Mol Med | 2020 | https://conductscience.org/library/papers/32860347 | PubMed |
| 32801835 | Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes. | Pharmgenomics Pers Med | 2020 | https://conductscience.org/library/papers/32801835 | PubMed |
| 31717544 | PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31717544 | PubMed |
| 31423128 | Induction of apoptosis and modulation of homologous recombination DNA repair pathway in prostate cancer cells by the combination of AZD2461 and valproic acid. | EXCLI J | 2019 | https://conductscience.org/library/papers/31423128 | PubMed |
| 30889466 | Nitric oxide-donor/PARP-inhibitor combination: A new approach for sensitization to ionizing radiation. | Redox Biol | 2019 | https://conductscience.org/library/papers/30889466 | PubMed |
| 30831275 | Cationic lipoplexes for treatment of cancer stem cell-derived murine lung tumors. | Nanomedicine | 2019 | https://conductscience.org/library/papers/30831275 | PubMed |
| 29579325 | A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer. | Cancer | 2018 | https://conductscience.org/library/papers/29579325 | PubMed |
| 29448954 | New therapeutic strategies to treat human cancers expressing mutant p53 proteins. | J Exp Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29448954 | PubMed |
| 28886696 | Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. | BMC Cancer | 2017 | https://conductscience.org/library/papers/28886696 | PubMed |
| 28577239 | Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers. | Cancer Chemother Pharmacol | 2017 | https://conductscience.org/library/papers/28577239 | PubMed |
| 27655368 | Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response? | Clin Transl Oncol | 2017 | https://conductscience.org/library/papers/27655368 | PubMed |
| 27308587 | Trial watch - inhibiting PARP enzymes for anticancer therapy. | Mol Cell Oncol | 2016 | https://conductscience.org/library/papers/27308587 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CHEK1 | 1111 | PubTator's text mining | https://conductscience.org/library/genes/1111 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| MRE11 | 4361 | PubTator's text mining | https://conductscience.org/library/genes/4361 | NCBI Gene |
| PARP1 | 142 | PubTator's text mining | https://conductscience.org/library/genes/142 | NCBI Gene |
| PTEN | 5728 | PubTator's text mining | https://conductscience.org/library/genes/5728 | NCBI Gene |
| RAD51 | 5888 | PubTator's text mining | https://conductscience.org/library/genes/5888 | NCBI Gene |
| RPA1 | 6117 | PubTator's text mining | https://conductscience.org/library/genes/6117 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23239809
GET https://conductscience.org/api/papers/v1/23239809/cited_by?page=2